Conjugate Vaccine: Efficacy Against WHO Priority Pathogens
Synthetic Bacteria Vaccine Against Antibiotics Resistant Bacteria
Tags: The University of Hong Kong, Hong Kong, Healthcare & Lifesciences
This technology develops vaccines against pseudaminic acid-carrying bacteria like Acinetobacter baumannii and Pseudomonas aeruginosa, targeting pathogens listed on the WHO's priority list. By conjugating pseudaminic acid with the CRM197 carrier protein, the vaccines have shown complete protection in mice against lethal doses. These vaccines offer a promising, cost-effective solution for bacteria that are currently hard to treat with existing antibiotics. They could significantly impact public health by preventing infections from these resistant bacteria.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Vaccines; Public Health & Universal Healthcare
